Hyderabad: Aurobindo Pharma subsidiary Acrotech Biopharma has forayed into the U.S. dermatology market with the launch of Adquey (difamilast 1%) ointment, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis.
The product will compete in a market estimated to be around $1.3 billion, the company said, citing IQVIA MAT numbers for the 12 months ended July 2026.
The launch marks Acrotech Biopharma’s entry into the dermatology segment in the U.S., expanding Aurobindo’s specialty portfolio.
Adquey is indicated for the treatment of mild-to-moderate atopic dermatitis and offers a non-steroidal option for patients, the company added.
